Status and phase
Conditions
Treatments
About
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
300 participants in 3 patient groups
Loading...
Central trial contact
Kala Patel, R.Ph., RAC; Takanori Nemoto, M.S.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal